OncoMatch

OncoMatch/Clinical Trials/NCT06503211

On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma

Is NCT06503211 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies UTAA09 for recurrent or refractory b-cell non hodgkin's lymphoma.

Phase 1RecruitingThe First Affiliated Hospital with Nanjing Medical UniversityNCT06503211Data as of Jun 2026Location: China

Treatment: UTAA09The main research objective is to evaluate the safety, tolerability, and pharmacokinetic characteristics of UTAA09 cell preparation in the treatment of relapsed/refractory B-cell non Hodgkin's lymphoma patients. The secondary research objective is to explore the clinical efficacy of UTAA09 injection after administration and to explore the content of CD19 positive B cells in peripheral blood after UTAA09 injection administration.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

UTAA09

Cancer type

Non-Hodgkin Lymphoma

Biomarker criteria

Required: CD19 positivity

Required: CD20 positivity

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75

Prior therapy

Cannot have received: chimeric antigen receptor therapy

Received other chimeric antigen receptor therapy or gene modified cell therapy before screening

Cannot have received: gene modified cell therapy

Received other chimeric antigen receptor therapy or gene modified cell therapy before screening

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06503211 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior chimeric antigen receptor therapy, gene modified cell therapy disqualifies patients from enrollment.

Does this trial require CD19?

Yes, CD19 positivity is a required biomarker for enrollment.

Does this trial require CD20?

Yes, CD20 positivity is a required biomarker for enrollment.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify